Literature DB >> 24903325

Phosphorylation of PAX3 contributes to melanoma phenotypes by affecting proliferation, invasion, and transformation.

Aditi S Iyengar1, Patrick J Miller, Jacob M Loupe, Andrew D Hollenbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24903325      PMCID： PMC4150824          DOI： 10.1111/pcmr.12277

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  8 in total

1.  PAX3 is expressed in human melanomas and contributes to tumor cell survival.

Authors:  F A Scholl; J Kamarashev; O V Murmann; R Geertsen; R Dummer; B W Schäfer
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

2.  Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts.

Authors:  Patrick J Miller; Kevin N Dietz; Andrew D Hollenbach
Journal:  Protein Sci       Date:  2008-08-15       Impact factor: 6.725

3.  Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Aditi S Iyengar; Jacob M Loupe; Andrew D Hollenbach
Journal:  Int J Biochem Cell Biol       Date:  2011-03-31       Impact factor: 5.085

4.  Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.

Authors:  Shu-Jie He; Graham Stevens; Antony W Braithwaite; Michael R Eccles
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

5.  PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.

Authors:  Shujie He; Caiyun G Li; Lynn Slobbe; Amy Glover; Elaine Marshall; Bruce C Baguley; Michael R Eccles
Journal:  Melanoma Res       Date:  2011-02       Impact factor: 3.599

6.  GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells.

Authors:  Jennifer D Kubic; Joseph B Mascarenhas; Takumi Iizuka; Don Wolfgeher; Deborah Lang
Journal:  Mol Cancer Res       Date:  2012-06-07       Impact factor: 5.852

7.  PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).

Authors:  Sandra Medic; Mel Ziman
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.

Authors:  Ralf Amstutz; Marco Wachtel; Heinz Troxler; Peter Kleinert; Margret Ebauer; Torsten Haneke; Christoph Oehler-Jänne; Doriano Fabbro; Felix K Niggli; Beat W Schäfer
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701
  8 in total
  5 in total

1.  Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Authors:  Jessica D Hathaway-Schrader; Bently P Doonan; Azim Hossain; Faisal F Y Radwan; Lixia Zhang; Azizul Haque
Journal:  J Cell Biochem       Date:  2017-10-18       Impact factor: 4.429

2.  Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options.

Authors:  J M Loupe; P J Miller; D R Ruffin; M W Stark; A D Hollenbach
Journal:  Oncogenesis       Date:  2015-03-30       Impact factor: 7.485

3.  Identification and functional analysis of SOX10 phosphorylation sites in melanoma.

Authors:  Julia C Cronin; Stacie K Loftus; Laura L Baxter; Steve Swatkoski; Marjan Gucek; William J Pavan
Journal:  PLoS One       Date:  2018-01-09       Impact factor: 3.240

4.  PAX3 is a biomarker and prognostic factor in melanoma: Database mining.

Authors:  Yong Liu; Shengnan Cui; Wenbin Li; Yiding Zhao; Xiaoning Yan; Jianqin Xu
Journal:  Oncol Lett       Date:  2019-03-18       Impact factor: 2.967

5.  Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.

Authors:  E C Maggi; J Trillo-Tinoco; A P Struckhoff; J Vijayaraghavan; L Del Valle; J S Crabtree
Journal:  Oncogenesis       Date:  2016-08-22       Impact factor: 7.485
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.